Opthea Limited: Secures US$35 million Commitment and Potential Additional US$50 million

Opthea Limited, (ASX: OPT), is on the brink of securing a considerable financial boost. The impending acquisition of the remaining US$35 million from the Development Funding Agreement (DFA) with Carlyle and Abingworth, coupled with the finalization of binding agreements with a new co-investor for an additional US$50 million, is poised to elevate the company's funding to a substantial US$170 million under the amended DFA.

This infusion, expected by December 31, 2023, maintains a critical distinction—it will be non-dilutive to existing shareholders, safeguarding their equity stakes by avoiding any issuance of equity to Carlyle, Abingworth, or the freshly engaged co-investor. The pivotal factor propelling this significant investment is the recognition of the potential held by sozinibercept (OPT-302) in revolutionizing visual outcomes for patients grappling with wet AMD. Opthea's advancement in this domain not only promises superior patient care but also presents an immense opportunity within the expansive multi-billion-dollar commercial landscape, underscoring the company's vision and potential for groundbreaking innovation in treating progressive retinal diseases.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com